The UC Davis spinout has collected $20m in series B capital from Bow Capital, a VC fund affiliated with the university.

Based on research conducted at University of Oxford and Netherlands Cancer Institute, Scenic Biotech has raised $7.3m to commercialise technology that tackles diseases on the genetic level.

Merck Ventures, which previously led a seed round in 2015, has returned to lead a series A round that featured fellow existing shareholder Novo Seeds.

The Stanford spinout has collected series A funding from investors including Johnson & Johnson and Osage University Partners.

The Stanford spinout has collected series A funding from investors including Johnson & Johnson and Osage University Partners.

Novartis and GlaxoSmithKline have returned to back a series B round that also attracted Singapore state-backed Vertex Ventures and university venturing fund Cambridge Innovation Capital.

Novartis and GlaxoSmithKline have returned to back a series B round that also attracted Singapore state-backed Vertex Ventures and university venturing fund Cambridge Innovation Capital.